Testing Compound Kushen injection for advanced colon cancer survival
Part of Cancer, Digestive system clinical trials.
This trial studies whether Compound Kushen injection can improve survival in people with advanced colorectal cancer. It’s aimed at people starting first-line treatment, and only includes certain cancer and health situations to keep results clear.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have advanced colorectal cancer confirmed by pathology or cytology
- Start first-line (first) treatment for your cancer
- Be age 18 or older, and able to take part in follow-up visits
- Your general health must be good enough (ECOG 0 to 2) and you expect to live at least 3 months
- Scans/tests must show at least one measurable tumor spot
- Not have certain exclusions (pregnancy/breastfeeding, other cancers, certain immune therapy/radiation recently, or drug allergies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new cancer treatment (YKYY031) given by injection for advanced colorectal or pancreatic cancer that has stopped responding to standard treatments. The drug is designed to target specific genetic changes (mutations) found in some tumors, and your immune system must match a particular genetic marker (HLA-A*11:01) for the drug to work.
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This Phase 1 trial tests KH617, a new treatment, in adults with advanced cancers to see if it can be given safely and whether it shows signs of benefit. It is especially focused on tumors that have few or no standard treatment options, including certain brain tumor recurrences.
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
Hear when a new Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.